Patient Selection for Aflibercept 8 mg

Opinion
Video

Panelists discuss how ideal candidates for aflibercept 8 mg include patients with stable disease on current anti-VEGF therapy who seek reduced treatment burden, newly diagnosed patients, and those demonstrating good response to initial loading doses.

Video content above is prompted by the following:

  • Who is the ideal patient for aflibercept 8 mg?

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
A person sits at their laptop with a cup of coffee visible in the foreground. Concept image for instant coffee, AMD, age related macular degeneration, ocular health and instant coffee investigation. Image credit: ©Ljustina – stock.adobe.com

Patients with high genetic risk of AMD should avoid instant coffee, investigators say

Lynda Charters
July 1st 2025
Article

Investigators obtained data from genome‐wide association studies to examine the effects of instant coffee consumption

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

Zeteo Biomedical receives new EU and US patents for its drug delivery technologies

Zeteo Biomedical receives new EU and US patents for its drug delivery technologies

Kassi Filkins
June 11th 2025
Article

ZTech-L and ZTech-P, as part of the ZTech portfolio, supports administering therapeutics in both liquid and dry powder formulations

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A bridge made from building blocks has an incomplete area. A hand reaches down with the missing block to close the gap. Concept image for age-related macular degeneration therapy and treatment article, IOL implantation and ophthalmology. Image credit: ©patpitchaya – stock.adobe.com

An implantable option bridges the gap for patients with AMD

Federico Badalà, MD
June 4th 2025
Article

Long-term benefits and vision preservation using an extended macular vision IOL

A person types on a computer. An AI brain is over the screen. Concept image for artificial intelligence, therapy planning assistant system, TPS, Europe, CE mark. Image credit: ©New Africa – stock.adobe.com

EU issues CE mark for AI therapy planning assistant from deepeye Medical

Jordana Joy
June 2nd 2025
Article

The therapy planning support tool has been trained on thousands of patient cases from more than 200 retina centres throughout Europe

© 2025 MJH Life Sciences

All rights reserved.